SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

tilrekimig

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
Phase 3 trials began enrolling in August 2026 with estimated primary completion dates in 2028-2029. If successful, a BLA submission would follow, with potential FDA approval likely no earlier than 2029-2030.
Why 3/10
No PDUFA date or pivotal topline readout is scheduled within the next ~12 months. Phase 3 trials began enrolling in August 2026 with primary completion dates estimated in 2028-2029. The next hard catalyst will be Phase 3 topline data, likely in late 2027 or later. Pfizer is a mega-cap diversified pharma, so even a positive readout would be a modest catalyst for the stock.
Actionable Insight NEUTRAL

The next hard catalyst for tilrekimig is the topline Phase 3 readout in atopic dermatitis, likely in late 2027 or 2028 given the trials started enrolling in August 2026 with 16-week primary endpoints. No PDUFA date or regulatory filing is expected within the next 12 months. For a Pfizer-sized company, positive Phase 3 data would be a modest positive but not a binary event; watch for enrollment completion updates and any early efficacy signals from the ongoing trials.

Price Chart

Loading chart...

Executive Summary

Tilrekimig (PF-07275315) is Pfizer's investigational first-in-class trispecific antibody that simultaneously blocks IL-4, IL-13, and TSLP, three key drivers of Type 2 inflammation. In October 2026, Pfizer presented positive Phase 2 data in moderate-to-severe atopic dermatitis showing 47.8% to 62.5% of patients achieved EASI-75 at week 16 across doses versus 9.1% to 19.9% for placebo. Based on these results, Pfizer has launched a broad Phase 3 program across atopic dermatitis (including a head-to-head trial against Sanofi/Regeneron's blockbuster Dupixent), severe asthma, and COPD. The drug is designed for once-monthly subcutaneous dosing. However, tilrekimig is still early in Phase 3 with no near-term binary catalyst, and Pfizer is a $200B+ diversified pharma where this is one of many pipeline programs, limiting near-term stock impact.

How It Works

Tilrekimig is a trispecific antibody (a single engineered protein that can bind to three different targets at once). It simultaneously blocks three immune-signaling proteins called interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP), which are key drivers of Type 2 inflammation in conditions like eczema (atopic dermatitis), asthma, and COPD. By blocking all three pathways with one drug given as a monthly shot, it aims to provide broader and more convenient control of allergic inflammation than existing treatments that block only one or two of these pathways.

Trial Status

Pfizer initiated Phase 3 trials in August 2026 across three indications. In atopic dermatitis, two Phase 3 trials are recruiting: a placebo-controlled study (NCT07765888, n=375) and a head-to-head monotherapy study against dupilumab/Dupixent (NCT07783425, n=1,375). In severe asthma, a Phase 3 placebo-controlled trial (NCT07772921, n=1,100) is recruiting. A Phase 2b/3 study in COPD is also ongoing. Phase 2 results were presented at EADV Congress in Vienna on October 1, 2026, meeting the primary EASI-75 endpoint at all doses tested.

The Two-Sided Case

▲ Bull Case5
Phase 2 data showed strong efficacy: 47.8% to 62.5% of patients achieved EASI-75 at week 16 across doses versus 9.1% to 19.9% for placebo, meeting the primary endpoint at all doses tested. The drug was well-tolerated with a favorable safety profile.
Potential first-in-class trispecific antibody simultaneously blocking three Type 2 inflammation drivers (IL-4, IL-13, and TSLP), which could offer broader efficacy than single-pathway blockers like Dupixent.
Once-monthly subcutaneous dosing (37-day half-life) could be a convenience advantage over Dupixent's every-two-week regimen, potentially driving patient and physician adoption.
Phase 3 program includes a head-to-head trial against Dupixent (NCT07783425), positioning tilrekimig to potentially demonstrate superiority and capture significant market share in the large atopic dermatitis market (estimated at $21B+ in 2026).
Pfizer is advancing tilrekimig across three large indications (atopic dermatitis, asthma, COPD), expanding the total addressable market significantly.
▼ Bear Case4
Faces entrenched competition from approved biologics: Sanofi/Regeneron's Dupixent (dupilumab, IL-4Rα blocker), Lilly's Ebglyss (lebrikizumab), and LEO Pharma's Adbry (tralokinumab), plus oral JAK inhibitors. Dupixent alone generated over $14 billion in 2025 sales and has a multi-year head start.
Phase 3 trials are just beginning (enrollment started August 2026) with primary completion estimates in 2028-2029. The drug is years away from potential approval, and Phase 3 failure risk remains significant despite promising Phase 2 data.
As a trispecific antibody, tilrekimig is a novel modality with manufacturing complexity and potential immunogenicity risks that could emerge in larger Phase 3 trials.
Pfizer is a $200B+ diversified pharma; tilrekimig is a small part of a vast pipeline. Even strong Phase 3 data would have a limited impact on PFE's share price.

Upcoming Catalysts

  • Phase 3 topline data readout in atopic dermatitis (likely late 2027 or 2028, no firm date set)
  • Phase 3 topline data readout in severe asthma (likely 2028-2029)
  • Phase 2b/3 COPD data readout
  • Potential presentation of additional Phase 2 data at future medical meetings

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 pfizer.com2 pfizer.com3 dermatologytimes.com4 alphapilot.tech5 clinicaltrials.gov6 clinicaltrials.gov7 fiercebiotech.com8 synapse.patsnap.com9 adisinsight.springer.com10 biopharmadive.com